Aurinia Pharmaceuticals Inc. (AUPH): M&A transaction — Aurinia completes acquisition of Kezar Life Sciences for $6.955/share plus CVR

Aurinia Pharmaceuticals Inc.

Offer price: $6.955 cash per share plus one contingent value right (CVR).
5,927,580 shares tendered (~80.24% of outstanding) as of Expiration Time on May 8, 2026.
Merger completed on May 11, 2026 under DGCL Section 251(h); no stockholder vote required.
Outstanding in-the-money options converted to cash spread plus CVRs; out-of-the-money options cancelled.
CVR Agreement dated May 11, 2026 with Broadridge as Rights Agent and Fortis Advisors as Representative.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Aurinia Pharmaceuticals Inc. completed an acquisition involving Kezar Life Sciences, Inc. for $6.955 in cash, plus one contingent value right (closed 2026-05-11).

Action: acquisition
Counterparty: Kezar Life Sciences, Inc.
Consideration: $6.955 in cash, plus one contingent value right
Closing: 2026-05-11

Exact text from the filing

On May 8, 2026, Parent completed a tender offer for (i) the acquisition of all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), by Parent through a tender offer (the “Offer”) for a price per share of the Common Stock of: (A) $6.955 in cash (the “Cash Amount”), payable without interest, plus (B) one contingent value right (a “CVR”) (together with the Cash Amount, the “Offer Price”); and (ii) the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger.

View on SEC.gov

24 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-020402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.